Introduction
Depsipeptide or FR901228 was isolated from Chromobacterium violaceum strain WB968 and subsequently shown to induce morphologic reversion of H-ras-transformed NIH 3T3 cells. 1 Depsipeptide has now been identified as a histone deacetylase (HDAC) inhibitor, with a mode of action similar to trichostatin A. [2] [3] [4] [5] These agents control chromatin function by inducing the hyperacetylation of specific lysine residues within positively charged N-termini protruding from the central histone octamer. 4 Hyperacetylation of histones appears to activate the transcription of significant numbers of repressed genes by facilitating their accessibility to RNA polymerase and transcription factors. 6, 7 Depsipeptide has also been shown to significantly increase the expression of genes delivered by recombinant viral, as well as by non-viral vector systems. [8] [9] [10] It induces enhancer-dependent transcriptional activation of an SV40 promoter-driven reporter gene approximately 10-fold more effectively than trichostatin A. 4 Furthermore, intratumoral administration of depsipeptide has been shown to increase significantly the expression of HVJ liposome-delivered genes injected directly into subcutaneous murine tumors. 9 The gene expression enhancing effects of HDAC inhibitors appear to be due, at least in part, to their ability to regulate endogenous genes that control the expression of transfected genes. 11 Previously, intravenous (i.v.) injection of 22 kDa linear PEI:DNA complexes has been shown to produce significantly higher levels of expression of delivered genes in a wide variety of different tissues than i.v.-injected lipoplex. 12, 13 Therefore, we assessed the ability of depsipeptide, intravenously co-injected with 22 kDa linear PEI:DNA complexes, to alter the expression of PEI-delivered genes in normal mice, and subsequently in mice bearing metastatic breast tumors. We first determined the effects of i.v. co-injecting depsipeptide with PEI:DNA complexes on the levels of reporter gene expression produced in a variety of different tissues in normal mice. Having identified the most effective depsipeptide dose and diluent, we then determined whether i.v. co-injection of depsipeptide significantly altered the expression of PEI-delivered genes in mice bearing metastatic 4T1 mammary carcinoma tumors. Depsipeptide differentially affects tumor cells versus normal cells. 4, 14, 15 Therefore, we assessed whether i.v. co-injection of depsipeptide with PEI:DNA complexes encoding the wild-type human p53 gene produced differential effects on human p53 expression in metastatic tumors versus in adjacent normal cells within tumor-bearing mice. Overall, these studies address a critical ongoing issue in in vivo gene delivery: identifying specific host factors that control the tissue-and cell typespecific expression of systemically delivered genes.
Results
We first assessed the effects of two different i.v. doses of depsipeptide on tissue expression levels of the firefly luciferase reporter gene, 24 h after i.v., 22 kDa PEI-based delivery. Specifically, 12.5 mg of a pCMV-luciferase expression plasmid 16 was complexed to 22 kDa PEI at a 4.5:1 N:P ratio. This N:P ratio produces high-level expression of delivered genes while minimizing associated host toxicity. 12, 13, 17 PEI:DNA complexes were formulated in either depsipeptide, solubilized in a polyethylene glycol (PEG)-ethanol-based solution, or in D5W (a standard lipoplex diluent 18, 19 ) without depsipeptide. I.v. depsipeptide doses of either 25 or 250 mg per mouse were assessed. Although injection of DNA:PEI complexes in 25 mg of depsipeptide increased luciferase activity in the spleen and lung, neither increase approached a level of statistical significance of Po0.05. In contrast, i.v. administration of DNA:PEI complexes in 250 mg of depsipeptide increased levels of luciferase activity approximately three-fold in the lung (Po0.05), four-fold in the liver (Po0.01) and nine-fold in the spleen (Po0.005). However, luciferase activity was not increased in the heart, ovary or brain ( Figure 1 ). (Luciferase activity in brain was not statistically significantly different between the 250 mg depsipeptide-and diluent -only injected groups). The addition of up to 250 mg of depsipeptide per mouse did not appear to alter the DNA:PEI toxicity profile, as assessed by body weight, activity level and histopathologic evaluation (data not shown). In other experiments, co-i.v. injection of 125 mg of depsipeptide did not significantly increase tissue expression levels of the PEI-delivered luciferase gene (data not shown). Overall, i.v. co-injection of 250 mg of depsipeptide with PEI:DNA complexes significantly increased luciferase gene expression in the lung, liver and spleen, but not in the heart, ovary or brain (Figure 1 ). This pattern of tissue enhancement indicates that depsipeptide acts to enhance preferentially the expression of i.v.-delivered genes selectively in some tissues, but not in others.
As the diluent itself can significantly alter tissue expression levels produced by i.v., lipoplex-delivered genes, 20 we tested whether the presence of ethanol and PEG, required to solubilize depsipeptide, contributed to the higher levels of gene expression depsipeptide produced in mice ( Figure 1 ). Specifically, we assessed tissue luciferase levels following i.v. injection of DNA: PEI complexes diluted in (A) ethanol and PEG with 250 mg per mouse of depsipeptide, (B) D5W or (C) ethanol and PEG without depsipeptide. I.v. injection of DNA:PEI complexes in depsipeptide increased luciferase activities at least four-fold in the spleen, at least six-fold in the lung and at least 18-fold in the liver (all Po0.05), when compared to i.v.-DNA:PEI complexes diluted in either D5W or 5% ethanol and PEG without depsipeptide ( Figure 2 ). Tissue luciferase levels did not differ significantly between mice receiving i.v.-DNA:PEI complexes diluted in D5W or 5% ethanol and PEG alone. Thus, depsipeptide-mediated enhancement of the expression of delivered genes was owing to depsipeptide itself, and was unrelated to the diluent used.
We then assessed whether i.v., co-injection of depsipeptide with DNA:PEI complexes could increase tissue and cellular expression levels of PEI-delivered genes in tumor-bearing mice. Specifically, we assessed whether depsipeptide increased gene expression in BALB/c mice bearing 4T1 murine breast carcinomas metastatic to lung. I.v. co-injection of depsipeptide increased tissue luciferase activities approximately three-fold in the Figure 1 Increased ability of PEI:DNA complexes plus depsipeptide versus PEI:DNA complexes alone to transfect specific tissues following i.v. injection into normal mice. Groups of ICR mice received 12.5 mg of pHCMV-LUC within PEI:DNA complexes at a 4.5:1 N:P ratio, either alone or co-administered with 25 or 250 mg of depsipeptide. Lung (a), heart, liver, ovary, brain and spleen (b) were harvested 24 h later, and analyzed for luciferase activity. All mouse experiments were repeated at least one time, yielding similar results each time. Figure 2 The increased ability of PEI:DNA complexes plus depsipeptide to transfect specific tissues does not depend on the diluent used. Groups of ICR mice received pHCMV-LUC within PEI:DNA complexes at a 1:4.5 N:P ratio in (A) 40% ethanol, 5% PEG 400 and 55% normal saline plus 250 mg of depsipeptide, (B) 5% dextrose in water alone or (C) 40% ethanol, 5% PEG 400 and 55% normal saline alone. All mice were killed 24 h later, and lung, liver and spleen were dissected out and analyzed for luciferase activity.
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spleen, seven-fold in the liver and 17-fold in the lung (all Po0.05), when compared to i.v. DNA:PEI complexes injected without depsipeptide. As seen previously in normal mice (Figure 1 ), luciferase activity was not increased in either the ovary or heart ( Figure 3 ). The pattern of organ enhancement produced by depsipeptide in tumor-bearing, BALB/c mice (increased gene expression targeted to the lung, liver and spleen, was comparable to that produced in normal, ICR mice (Figures 1 and 2) . However, the level of enhancement of gene expression produced by depsipeptide in the lungs of tumor-bearing mice ( Figure 3 ) was higher than that produced in normal mice (Figures 1 and 2 ). In addition, the gene transfer efficiency of i.v. PEI:DNA complexes alone differed significantly in the lungs of ICR ( Figure 1 ) versus BALB/c (Figure 3 ) mice. Strain-specific differences in non-viral, systemic gene transfer efficiency have already been documented. 20 These, as well as differences in the efficiency of gene delivery produced in normal cells versus metastatic tumor cells, may play important roles both in depsipeptide-mediated enhancement of gene transfer efficiency and in the differences observed between BALB/c and ICR mice. Therefore, we assessed whether i.v. depsipeptide differentially affects the expression of i.v., PEI-delivered genes in metastatic tumor cells versus normal cells in tumor-bearing, BALB/c mice. Specifically, we i.v. injected identical DNA:PEI complexes encoding the wild-type human p53 gene, either with or without depsipeptide, into groups of BALB/c mice bearing advanced 4T1 tumor metastases. Mice were killed 24 h later and tumor-bearing lungs assayed for human p53 immunoreactivity. Wild-type human p53 immunoreactivity is not detectable in the lungs of normal mice, 21 and 4T1 mammary carcinoma cells are null/null for endogenous p53. 22 Therefore, expression of the PEI-delivered human wild-type human p53 gene can be readily detected above the undetectable p53 levels present both in normal murine lung cells as well as in p53-null, 4T1 cells metastatic to lung. 21, 22 Previously, systemic delivery of plasmid DNA complexed to 22 kDa linear PEI has been shown to transfect large numbers of normal lung cells, but not tumor cells metastatic to the lung. 17 We found that, as previously reported, 17 i.v. DNA:PEI complexes without depsipeptide efficiently transfected normal lung cells (Figure 4c and Table 1 ), but largely failed to transfect metastatic lung tumors ( Figure 4a and Table 1 ). I.v. co-injecting depsipeptide with DNA:PEI complexes did not increase the percentage of normal lung cells transfected with human p53 (Figure 4d and Table 1 ). Overall, 12.473.1% of normal lung cells were transfected with human p53 in tumor-bearing mice receiving DNA:PEI p53 complexes Figure 3 Increased ability of PEI:DNA complexes plus depsipeptide versus PEI:DNA complexes alone to transfect specific tissues following i.v. injection into tumor-bearing mice. Groups of BALB/c mice received 50 000 4T1 cells mammary carcinoma cells by tail vein injection on day 0. On day 20, each tumor-bearing mouse then received 12.5 mg of pHCMV-LUC within PEI:DNA complexes at a 4.5:1 N:P ratio, either alone or co-administered with 250 mg of depsipeptide. All mice were killed 24 h later, and lung (a), heart, liver, ovary and spleen (b) were dissected out and analyzed for luciferase activity. (Figures 1 and 2 ), but failed to increase the overall percentage of normal lung cells transfected ( Figure 4d and Table 1 ). Taken together, these data are most consistent with the hypothesis that depsipeptide is able to increase both the level of gene expression per transfected tumor cell as well as the absolute number of metastatic tumor cells transfected. In contrast, depsipeptide is able to increase the absolute level of gene expression per transfected normal cell, but not the overall number of normal cells transfected. This hypothesis is consistent with the prior literature showing that depsipeptide preferentially affects tumor cells when compared to normal cells. 1, 9, 15 Having determined that i.v. co-injection of depsipeptide can significantly increase the efficiency of PEI:DNAbased gene delivery, we then assessed whether it also alters HDAC activity in relevant tissues of injected mice. Thus, we directly tested the effects of i.v. co-injection of depsipeptide versus diluent only on tissue HDAC activity, as measured by a colorimetric assay. 23 Specifically, we injected groups of three ICR mice with DNA:PEI complexes diluted in either 250 mg per mouse of depsipeptide in 5% ethanol and PEG or in 5% ethanol and PEG without depsipeptide. As seen previously (Figure 1 ), i.v. co-injection of depsipeptide significantly increased luciferase activity in the lung and spleen of injected mice (data not shown). In addition, i.v. injection of depsipeptide significantly inhibited HDAC activity in the lung and spleen when compared to these tissues from diluent-only injected, control mice ( Figure 5) . Thus, i.v. co-injection of depsipeptide significantly decreases HDAC activity in the same tissues where it concurrently enhances the efficiency of PEI:DNA-based gene transfer. Overall, these results are consistent with the hypothesis that depsipeptidemediated reduction of tissue HDAC activity plays a role in increasing the efficiency of systemic, non-viral gene delivery in selected tissues.
Discussion
Aberrant acetylation of histones has now been linked to tumorigenesis. 2, 4 The HDAC inhibitor, depsipeptide, can induce apoptosis, 3 growth inhibition 1 and differentiation of tumor cells. 4, 14 Furthermore, direct intratumoral administration of depsipeptide can significantly increase both the levels of expression of delivered genes and the antitumor effects produced by non-viral approaches in mice. 9, 24 Specifically, local administration of depsipeptide with HVJ liposomes directly into subcutaneous B16 melanoma tumors increased reporter gene activity 3.3-fold in injected tumors. Intratumoral injection of depsipeptide increased the expression of HVJ-delivered genes within tumors 5-10 times more effectively than either its i.v. or intraperitoneal (i.p.) injection. 9 Furthermore, direct intratumoral injection of HVJ liposomes expressing the herpes simplex virus (HSV) thymidine kinase (TK) gene plus depsipeptide, together with i.p. ganciclovir administration, significantly reduced tumor size when compared to HSV-TK-ganciclovir therapy without depsipeptide. Repeated, HVJ-mediated intratumoral injection of HSV-TK with ganciclovir plus depsipeptide significantly increased overall survival when compared to HSV-TK-ganciclovir therapy alone. 24 More recently, i.v., single-agent administration of depsipeptide has been shown to produce significant antitumor activity in a subset of human patients with either chronic lymphocytic leukemia or T-cell lymphoma. 25, 26 We now show that systemic co-injection of depsipeptide can significantly increase the efficiency of i.v., PEIbased gene transfer in selected tissues and cell types. Co-injection of depsipeptide in normal mice enhanced the efficiency of gene expression specifically in the lung, liver and spleen. The mechanism by which i.v. depsipeptide achieves its tissue-targeted, expression-enhancing Figure 5 Colorimetric assay for HDAC activity. ICR mice were transfected with PEI-DNA complexes with or without depsipeptide. Twenty-four hours after transfection, mice were killed. Lung and spleen were removed, nuclear extracts isolated and colorimetric assay for HDAC activity performed, as described in the Materials and methods section. Role of depsipeptide in transfection Y Liu et al effects is presently uncharacterized. Previously, i.v., lipoplex-delivered expression plasmid DNA has been shown to accumulate at high levels in the lung and liver. 16, 27 However, plasmid DNA taken up by the liver was expressed very inefficiently. 16, 27 Subsequently, the use of HDAC inhibitors was shown to increase significantly the expression of intercellularly delivered, but poorly expressed plasmid DNAs. 11 Thus, the preferential effects of depsipeptide on plasmid DNA delivered into cells within the liver may be due, at least in part, to the ability of HDAC inhibitors to increase the expression of intercellularly delivered, but poorly expressed genes. 11 Alternatively, different patterns of chromosomal gene regulation in different cell types may also play important mechanistic roles in determining whether, and to what extent depsipeptide increases the efficiency of non-viral gene delivery in specific tissues. In a number of different cell types, depsipeptide has been shown to significantly up-or downregulate from 1 to 5% of the cellular genes assayed. 14, 28, 29 Recently, depsipeptide has been shown to significantly up-or downregulate the expression of 420% of all cellular genes assayed in cultured human Tlymphoid leukemia cells (CEM) tumor cells. 30 Thus, depsipeptide appears to regulate a significantly different proportion of cellular genes in different cell types. 14, 28, 29 For example, some of the genes regulated by HDAC inhibitors include p21 WAF1/Cip1 interleukin-8, JunB and cyclin A.
14 Recently, p21 WAF1/Cip1 gene expression has been reported to affect significantly the expression of transduced genes. 31 Thus, HDAC inhibitors may selectively induce the expression of endogenous genes within certain cell types that regulate the expression of transfected genes.
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The ability of i.v. co-injected depsipeptide to preferentially increase gene expression in metastatic tumor cells (Figure 4 ) is consistent with prior reports that HDAC inhibitors affect tumor cells quite differently than normal cells. 1, 9, 14 For example, the IC 50 values of depsipeptide against human tumor cells are in the 1 ng/ml range versus 41 mg/ml against normal human fibroblasts.
1 Thus, depsipeptide is approximately 1000-fold more active against tumor cells than against normal cells. Furthermore, genes including caspase-9 and mitogen-activated protein kinase phosphate-1 are differentially regulated by depsipeptide in depsipeptide-sensitive versus resistant tumors.
14 In addition, depsipeptide has been shown to arrest dividing tumor cells in the G1 and G2/M phases of the cell cycle. 14 Previously, synchronizing tumor cells in G2M has been shown to render them significantly more transfectable by non-viral methods. 32, 33 The abilities of i.v. depsipeptide to enhance specifically the expression of systemically delivered genes in selected tissues, as well as in metastatic tumor cells may allow more precise targeting of anticancer gene therapy approaches, particularly those directed against tumor metastases in the lung, liver and spleen. To confer even more precise targeting of liganddirected 34, 35 as well as of promoter-targeted 36 gene therapies, it will be necessary to better understand the host factors that regulate the tissue and cellular expression levels of systemically delivered genes. These results show that HDACs play a significant role in determining tissue and cell-types specific responses to genes delivered systemically by non-viral vectors.
Materials and methods
Plasmids P4377 (pHCMV-luc) 16 and p4214 (pHCMV-hu-p53) 21 were constructed, and plasmid DNA purified as described previously. 16 
Preparation of PEI
Linear PEI (22 kDa ) was prepared and complexation of PEI with plasmid DNA was performed as described previously.
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Tumor cell lines 4T1 mammary carcinoma cells were freshly thawed and grown in 5% FBS in minimal essential medium media at 371C with 5% CO 2 for 48 h. On day 0, groups of 6-weekold female BALB/C mice (Simonsen, Gilroy, CA, USA) were i.v. injected by tail vein with 50 000 4T1 cells in 200 ml of culture medium. For experiments in tumorbearing mice, BALB/c mice in groups of three were each i.v. injected with 50 000 4T1 tumor cells, 38 25 days before receiving i.v., PEI:DNA complexes. Individual BALB/c mice then each received i.v., PEI:DNA complexes in 300 ml total volume containing either 12.5 mg of pHCMVluc (experiment 3) or 12.5 mg of pHCMV-human p53 (experiment 4), complexed to 22 kDa linear PEI at a 4.5:1 N:P ratio, with or without i.v.-co-injected depsipeptide.
Animals
Six-week-old female ICR (CD-1) mice were purchased from Charles River (Hollister, CA, USA). Six-week-old female BALB/c mice were purchased from (Simonsen, Gilroy, CA, USA). All mice were certified to be free of common murine pathogens. All mice were housed in the CPMCRI animal care facility for 1 week before receiving treatment.
I.v. injection of PEI:DNA complexes, with or without depsipeptide
Depsipeptide was kindly provided by the NIH RAID mechanism as gift. Depsipeptide (2.5 mg) was dissolved in a 1 ml solution containing 40% ethanol (Gold Shield Chemical, Hayward, CA, USA), 5% PEG 400 (Sigma, St Louis, MO, USA) and 55% normal saline. A measure of 25-250 mg of depsipeptide per mouse was mixed together with DNA-PEI complexes for i.v. injection. Individual CD-1 mice in groups of five each received i.v., PEI:DNA complexes in 300 ml total volume containing 12.5 mg of pHCMV-luc complexed to 22 kDa linear PEI at a 4.5:1 N:P ratio, with or without depsipeptide. Twentyfour hours after injection, all mice were killed and tissues (lung, spleen and liver, as well as in some experiments, ovary, heart and/or brain) were collected and assayed for luciferase activity, as described below. The 24 h time point was chosen for killing because it represents a time of peak luciferase levels following i.v. lipoplex-based delivery. 12, 16, 26 The in vivo effects of a single depsipeptide injection should be time limited. 9 
Assay of Luciferase activity
Fresh tissue samples were placed in lysis buffer (Promega Luciferase Assay System, Madison, WI, USA), homogenized and then spun for 10 min at 8000 r.p.m. at room temperature in a table-top centrifuge.
Role of depsipeptide in transfection Y Liu et al Supernatant (20 ml) was assayed with 0.1 ml luciferase assay substrate (Promega) in a Monolight 2010 luminometer (Analytical Luminescence Laboratory). Relative light units (RLU) were first normalized to micrograms of tissue protein added in the luciferase assay. RLU were then converted to luciferase protein using a reference standard curve derived by measuring purified luciferase protein standards purchased from Analytical Luminescence Laboratory. Luciferase protein levels were corrected for tissue quenching by measuring the luciferase protein standards in tissue extracts from untreated control animals. 16 The potential statistical significance of differences was assessed using an unpaired, two-sided Student's t-test.
Assessment of p53 gene expression by immunohistochemistry. Twenty-four hours after injection of PEI:pHCMV-human p53 with or without depsipeptide, BALB/c mice were killed and tissues from injected and control mice were harvested, processed, stained and analyzed for wild-type human p53 immunoreactivity as described previously. 21 
Assessment of HDAC activity by colorimetric assay
Twenty-four hours after injection of PEI:pHCMV-luciferase with or without depsipeptide, CD1 mice were killed and tissues from injected and control mice were harvested, and lung and spleen removed. Nuclear extracts were then prepared, as described previously. 23 Assays were performed using a colorimetric HDAC activity assay from BioVision Research Products according to the manufacturer's instructions. Briefly, 85 mg of nuclear extract from each tissue was diluted in 85 ml of ddH 2 O; 10 ml of 101C HDAC assay then buffer added, followed by the addition of 5 ml of the colorimetric substrate. Samples were incubated at 371C for 1 h and the reaction was then stopped by adding 10 ml of lysine developer and incubated for an additional 30 min at 371C. Samples were then read in an enzyme-linked immunosorbant assay plate reader at 400 nm. A standard curve was prepared using known amounts of deacetylated standard. 23 
